-
The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
Spencer K, Bindra R, Cacho AM, Nicolaides KH.
Prenat Diagn 2004;24:169-73. -
A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A.
Spencer K, Nicolaides KH.
Prenat Diagn 2002;22:877-9. -
One-stop clinic for assessment of risk of chromosomal defects at 12 weeks of gestation.
Nicolaides KH, Bindra R, Heath V, Cicero S.
J Matern Fetal Neonatal Med 2002;12:9-18. -
Fetal nasal bone length in chromosomally normal and abnormal fetuses at 11-14 weeks of gestation.
Cicero S, Bindra R, Rembouskos G, Tripsanas C, Nicolaides KH.
J Matern Fetal Neonatal Med 2002;11:400-2. -
One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies.
Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH.
Ultrasound Obstet Gynecol 2002;20:219-25. -
Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta -hCG and PAPP-A at 10-14 weeks of gestation.
Tul N, Spencer K, Noble P, Chan C, Nicolaides K.
Prenat Diagn 1999;19:1035-42. -
A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;13:231-7.